X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs BIOCON LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. BIOCON LTD FRESENIUS KABI ONCO./
BIOCON LTD
 
P/E (TTM) x 22.1 50.9 43.5% View Chart
P/BV x 3.1 7.4 42.0% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 FRESENIUS KABI ONCO.   BIOCON LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
BIOCON LTD
Mar-18
FRESENIUS KABI ONCO./
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1761,188 14.8%   
Low Rs79305 25.7%   
Sales per share (Unadj.) Rs37.768.7 54.8%  
Earnings per share (Unadj.) Rs5.17.6 67.4%  
Cash flow per share (Unadj.) Rs6.714.0 48.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs42.586.3 49.3%  
Shares outstanding (eoy) m158.23600.00 26.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.410.9 31.1%   
Avg P/E ratio x25.098.9 25.3%  
P/CF ratio (eoy) x18.953.4 35.4%  
Price / Book Value ratio x3.08.6 34.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m20,135447,900 4.5%   
No. of employees `0001.26.1 18.7%   
Total wages/salary Rs m7039,311 7.6%   
Avg. sales/employee Rs Th5,176.26,705.8 77.2%   
Avg. wages/employee Rs Th610.41,514.2 40.3%   
Avg. net profit/employee Rs Th699.6736.9 94.9%   
INCOME DATA
Net Sales Rs m5,96341,234 14.5%  
Other income Rs m182,062 0.9%   
Total revenues Rs m5,98143,296 13.8%   
Gross profit Rs m1,4308,291 17.2%  
Depreciation Rs m2583,851 6.7%   
Interest Rs m-26615 -4.2%   
Profit before tax Rs m1,2165,887 20.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,569 21.8%   
Profit after tax Rs m8064,531 17.8%  
Gross profit margin %24.020.1 119.3%  
Effective tax rate %28.126.7 105.6%   
Net profit margin %13.511.0 123.0%  
BALANCE SHEET DATA
Current assets Rs m5,10241,486 12.3%   
Current liabilities Rs m2,38521,413 11.1%   
Net working cap to sales %45.648.7 93.6%  
Current ratio x2.11.9 110.4%  
Inventory Days Days15064 234.6%  
Debtors Days Days11394 120.3%  
Net fixed assets Rs m5,14850,661 10.2%   
Share capital Rs m1583,000 5.3%   
"Free" reserves Rs m6,55648,808 13.4%   
Net worth Rs m6,73251,808 13.0%   
Long term debt Rs m95217,898 5.3%   
Total assets Rs m10,38899,897 10.4%  
Interest coverage x-45.810.6 -433.0%   
Debt to equity ratio x0.10.3 40.9%  
Sales to assets ratio x0.60.4 139.1%   
Return on assets %7.55.2 145.7%  
Return on equity %12.08.7 136.9%  
Return on capital %14.69.6 151.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29812,058 43.9%   
Fx outflow Rs m1,7727,348 24.1%   
Net fx Rs m3,5254,710 74.8%   
CASH FLOW
From Operations Rs m1,2746,621 19.2%  
From Investments Rs m-1,204-6,840 17.6%  
From Financial Activity Rs m-196-2,397 8.2%  
Net Cashflow Rs m-126-2,612 4.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 81.0 20.6 393.2%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 9.6 10.7 89.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   42,599 109,995 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SUN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS